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Background: Adiponectin’s effects on systemic physiology and cell-specific responses are well-defined, but little is
known about how this insulin-sensitizing and anti-inflammatory adipokine reaches its target cells. All molecules face
active and passive transport limitations, but adiponectin is particularly noteworthy due to the diverse size range
and high molecular weights of its oligomers. Additionally, its metabolic target organs possess a range of endothelial
permeability.
Methods: Full-length recombinant murine adiponectin was produced and oligomer fractions isolated by gel
filtration. Adiponectin complex sizes were measured by dynamic light scattering to determine Stokes radii.
Transendothelial transport of purified oligomers was quantitatively assessed under a number of different conditions
in vitro using murine endothelial cells and in vivo using several mouse models of altered endothelial function.
Results: Adiponectin oligomers exhibit large transport radii that limit transendothelial transport. Oligomerization is
a significant determinant of flux across endothelial monolayers in vitro; low molecular weight adiponectin is
preferentially transported. In vivo sampled sera from the heart, liver, and tail vein demonstrated significantly
different complex distribution of lower molecular weight oligomers. Pharmacological interventions, such as PPARγ
agonist treatment, differentially affect adiponectin plasma clearance and tissue uptake. Exercise induces enhanced
adiponectin uptake to oxidative skeletal muscles, wherein adiponectin potently lowers ceramide levels. In total,
endothelial barriers control adiponectin transport in a cell- and tissue-specific manner.
Conclusions: Adiponectin oligomer efficacy in a given tissue may therefore be endothelial transport mediated.
Targeting endothelial dysfunction in the metabolic syndrome through exercise and pharmaceuticals may afford an
effective approach to increasing adiponectin’s beneficial effects.
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With the alarming rise of obesity and obesity-related dis-
eases, understanding the endocrine functions of adipose
tissue and adipocyte-secreted adipokines in regulating
systemic metabolism and insulin sensitivity has become
critical. Inversely expressed with obesity, the adipokine
adiponectin has overall positive insulin-sensitizing and
metabolic effects via signaling in various tissues such as
liver and skeletal muscle. Adiponectin is unique in its* Correspondence: philipp.scherer@utsouthwestern.edu
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unless otherwise stated.post-translational modifications that result in secreted
oligomers of 90 kDa trimers, 180 kDa hexamers (LMW)
and 18- and potentially 36-mers in found in circulation
[1,2]. Our laboratory has demonstrated differential effi-
cacy of various sized adiponectin complexes on systemic
insulin sensitivity with the high molecular weight (HMW)
oligomers, or HMW:Trimer ratio, correlating best with in-
sulin sensitivity in both mouse and human studies [2-6].
Tranport of large proteins, lipoproteins, and chylomi-
crons occurs through open fenestrations (100–200 nm
pores) across filter or secretory tissue endothelium (e.g., liver
or adipose tissue) [7]. Other tissues, such as healthy lung,
heart and skeletal muscle, lack fenestrae and thus have
‘tighter’ endothelial transport barriers [8]. Under healthy
conditions in these blood vessels, paracellular endothelialral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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transport of molecules with Stokes radii greater than ap-
proximately 3 nm across continuous endothelia, such as
the tight endothelial barriers in skeletal muscle, requires
active transport through mechanisms ranging from caveo-
lar vesicular trafficking to the formation of transient trans-
endothelial pores [9]. The endothelium is also a plastic
transport barrier, as an array of cytokines and growth fac-
tors alter barrier function through modulating endothelial
nitric oxide synthesis, cell-cell junctions, and trans-cellular
trafficking mechanisms [10-13]. With endothelial dysfunc-
tion in obesity arising from altered insulin signaling or fatty
acid-induced inflammation, these transport mechamisms
are compromised [10,13,14]. Changes in endothelial func-
tion and hormone transport thus, in turn, affect tissue and
whole body metabolic function. For example, transendothe-
lial transport is a necessary step in insulin uptake to skeletal
muscle despite insulin’s small size compared to other hor-
monal factors [15]; genetic manipulations that result in al-
tered vascular endothelial permeability alter insulin uptake
and action [16,17]. Due to the potential transport limita-
tions of adiponectin, in particlular its highly beneficial
HMW form, we propose that the endothelium presents a
transport barrier to adiponectin that significantly affects its
access to target cells.
We have previously demonstrated that the clearance
time of adiponectin from the circulation is dependent
on oligomer size [18]; metabolic dysfunction induced by
high fat diet or the ob/ob mutation significantly reduced
clearance. To quantify the transport limitations of adipo-
nectin across endothelium, we produced full-length re-
combinant murine adiponectin and isolated from this
purified HMW, LMW, and trimeric oligomer prepara-
tions. We calculate the transport parameters of each
oligomer in vitro using dynamic light scattering and
murine endothelial cell monolayers. In vivo, we quantify
the effects of nitroglycerine and PPARγ-agonist treat-
ment on adiponectin oligomer circulatory half-life and
tissue fate. We find that exercise significantly increases
adiponectin uptake and action in oxidative skeletal
muscle. The non-trivial transendothelial transport of adi-
ponectin oligomers is therefore an important and poten-
tially rate-limiting factor for adiponectin to mediate its
positive systemic effects.
Methods
Protein production and labeling
Several milligrams of full-length murine adiponectin was
produced in stably transfected HEK 293 T cells as previ-
ously described to generate a mix of HMW, LMW, and
trimeric forms [5]. Adiponectin was repeatedly fraction-
ated using an ÁKTA FPLC system (GE Healthcare Bio-
Sciences Corp., Piscataway, NJ) and Superdex 200 10/300
GL column (GE Healthcare), 200 μg per load, into 250 μLfractions in 20 mM Tris buffer (pH = 8.0) [2]. Adiponectin
oligomer distribution was determined by immunoblotting
of the first 24 fractions as previously described [19].
Briefly, 4 μL of dithiothreitol containing Laemmli buffer
was added to 20 μL of the first 24 fractions and the samples
were heated at 95 ºC for 5 minutes. 20 μL of the mixture
was loaded onto 26-well Bio-Rad Criterion XT Bis-Tris gels
(4-12%) (Hercules, CA), separated by electrophoresis, trans-
ferred to nitrocellulose membranes and immunoblotted
with a rabbit polyclonal sera against murine adiponectin
[2]. Membranes were scanned on an LI-COR Odyssey in-
frared imaging system following secondary labeling with a
goat anti-rabbit IR800 antibody (LI-COR).
Eluted fractions, designated by valleys in fraction immu-
noblot intensity, containing each oligomer were combined
to obtain pure HMW, LMW, and trimeric preparations
and concentrated to 1.0 mg/mL. [The exact fraction num-
bers pooled varied by preparation; pools were normalized
batch-to-batch by collecting each species peak as identi-
fied by immunoblot intensity]. The purity of each final
oligomer preparation was assessed by repeating the frac-
tionation for immunoblotting. The percent of each species
represented was calculated as sum of raw intensities for
the given species fractions over the total intensities nor-
malized to the peak value, as measured in the Odyssey
software. Intensities are graphed as smoothed data
(0th order, 2-neighbor smoothing) in Prism software
(GraphPad Software, Inc.).
Full-length preparations and individual oligomer species
were used in vitro; HMW and LMW preps were used
in vivo. Globular murine adiponectin (gAPN) (lacking adi-
ponectin’s collagenous domain; 16.6 kDa) was purchased
for comparison (PeproTech, Rocky Hill, NJ). Mouse IgGs
were purchased from Sigma-Aldrich (St. Louis, MO).
HMW, LMW, and gAPN were labeled with LI-COR
(Lincoln, NE) IRDye 800CW and IgGs labeled with
IRDye 700DX (all at 1:1 molar ratios) according to
the manufacturer’s protocol. 3 kDa Alexa594 dextran
(Invitrogen, Carlsbad, CA) was used as a permeability
control throughout.
Adiponectin Oligomer Physical Size Measurements
Full-length recombinant adiponectin and the prepared
fractions were measured by dynamic light scattering
(DLS) on a temperature controlled Protein Solutions
DynaPro Molecular Sizer. Dextrans, mouse IgG, and
BSA were also measured for standards. Measurements
were made at 25°C. Sizes were calculated in Dynamics
V6.3.40 software after adjusting the baseline cutoffs such
that the regularization fit matched the intensity auto
correlations. A linear polysaccharide estimation was ap-
plied to dextrans and globular protein estimation used
for the proteins. The three predominant species ob-
served in measuring the full-length preparation were the
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then only that peak fit for correlation precision. Multiple
values were accepted and averaged with small changes in
the upper baseline cutoff. All solutions were thrice mea-
sured at concentrations of approximately 10 μg/mL. Pre-
sented values are measured averages of three separate
production preparations.
Animals
Male FVB mice, aged 12–16 weeks were utilized for
assessing adiponectin circulatory clearance. All mice
were maintained with ad libitum access to water and
standard chow throughout each experimental period.
Age and weight-matched pairs were grouped for each in-
jection (averaging 28-30 g). Caveolin-1 knockout mice
were used on a fully backcrossed FVB background and
compared to wild type matched litters [20]. Animal pro-
tocols were approved by the Institutional Animal Care
and Use Committee at UT Southwestern Medical
Center.
Experimental treatments
Mice in the PPARγ agonist group were provided pow-
dered standard chow diet containing 0.5 μg/g of the
non-thiazolidinedione (nTZD) PPARγ agonist compound
COOH [2-(2-(4-phenoxy-2-propylphenoxy)ethyl)indole-5-
acetic acid] (a kind gift from Merck & Co., Inc. [21,22])
for one week prior to circulatory studies. Control mice
also received powdered chow. For acute nitroglycerine cir-
culatory studies, mice were gavaged 30 minutes prior to
adiponectin injection with 1 mg/kg isosorbide dinitrate
(CorePharma, Middlesex, NJ) [23,24]. Ground tablets
were prepped in 2% Tween 80 in water (approximately
50 μL/gavage) with gavages repeatedly hourly. Control
mice received equivalent volumes of 2% Tween 80 in
water. Caveolin-1 knockout mice, previously described to
exhibit increased paracellular albumin flux [25], were used
without manipulation and compared to wildtype matched
litters.
In vitro endothelial permeability assay
Model murine endothelial cells lines, MS1, bEnd.3
(Bend), and EOMA, were acquired from ATCC (Manas-
sas, VA) and maintained in DMEM (4 mmol/L L-glu-
tamine, 4500 mg/L glucose, 1 mmol/L sodium pyruvate,
and 1500 mg/L sodium bicarbonate) supplemented with
10% FBS and 0.5% pen strep (all from Thermo Scientific
HyClone, Logna, UT). All cells were used at passages 3–
5 from the supplier. Endothelial cells were seeded at a
high density in transwell inserts (Corning, Tewksbury,
MA) sized for 12-well plates. Polycarbonate membrane
inserts were used for transport studies and polyester in-
serts were used for imaging, all with 3.0 μm pore sizes.
Dextran flux was assessed to determine the experimentaltimeframe of 6 hours, in agreement with previous work
with large molecule transport [26]. 6 hours prior to the
experiment, cell medium was changed to 2% FBS. 10 μg/
mL adiponectin and dextran were applied above the
monolayer (luminal side) to the top well. After 6 hours,
top (that above the monolayer) and bottom (below the
cells and membrane) media were assessed for adiponec-
tin and dextran concentrations by gel electrophoresis (as
above) and fluorescence intensity measurements, re-
spectively, and concentrations calculated by comparison
to standard curves prepared in culture medium. Dextran
fluorescence was measured on a POLARStar OPTIMA
fluorescence plate reader (BMG LABTECH GmbH,
Ortenberg, Germany). Permeability was calculated as
previously detailed [26] using the known starting top
concentrations and quantified bottom species concentra-
tions. For dynamin inhibition 20 μL of 80 μmol/L Dyna-
sore (Sigma) in DMSO was applied to the lower well
30 minutes prior to adiponectin (DMSO used as con-
trols). The adiponectin oligomer distribution when full-
form adiponectin was applied was assessed in the top
and bottom media after 6 hours described as above.
Cell-cell junctions were identified by an anti-mouse VE-
Cadherin antibody (R&D Systems, Minneapolis, MN) la-
beled by an Alexafluor488-conjugated donkey anti-goat
secondary antibody (Life Technologies). Fluorescence
and IR800-labeled adiponectin were imaged on a Leica
TCS SPF confocal microscope. At the end of experi-
ments, RNA was isolated from cell monolayers using the
Qiagen RNeasy Mini kit according the manufacturer’s
instructions (Qiagen GmbH, Hilden, Germany). cDNA
was synthesized using the iScript cDNA Synthesis Kit
(Bio-Rad). Expression was quantified on an Applied Bio-
systems 7900 lightcycler using primers as listed in the
Additional file 1: Table S1. Results are expressed relative
to basal MS1 cell levels.
Circulatory half-life quantifications
Endogenous tissue venous oligomer distributions were
determined in sera collected from the tail vein, portal
vein, and left ventricle under anesthesia using gel filtra-
tion as above and as described previously [2]. The clear-
ance of exogenous HMW and LMW adiponectin were
determined by quantifying the concentration of IR800-
labeled injected adiponectin as previously described [18]:
0.05 μg/g adiponectin, IR700-labeled mouse IgG, and
dextran were injected intravenously via the tail vein. Ap-
proximately 10 μL of blood was sampled from the tail
tip into heparinized tubes at each time point for up to
180 minutes. DTT-denatured sera was separated by gel
electrophoresis on Bio-Rad Criterion XT Bis-Tris gels
(4-12%) for each time point. Gels were immediately
scanned on an LI-COR Odyssey infrared imaging system
to directly visualize and quantify the 32 kDa and 25 kDa
Rutkowski et al. Cardiovascular Diabetology 2014, 13:47 Page 4 of 14
http://www.cardiab.com/content/13/1/47adiponectin and IgG light-chain bands, respectively. Gels
were transferred to nitrocellulose membranes and la-
beled for total murine IgG light-chain with a LI-COR
goat anti-mouse IR700 antibody (1:5000) for total serum
loading. Additionally, serum dextran fluorescence was
scanned on a POLARStar OPTIMA fluorescence plate
reader; 2 μL sera were added to 48 μL TBS to ensure the
well bottoms were covered. Half-lives were calculated
using a non-linear regression (decay) analysis of adipo-
nectin:IgG ratios in Prism software.
At 180 minutes, mice were perfused through the left
ventricle with 20 mL PBS under while under isofluorane
anesthesia and sacrificed. Tissues were excised and im-
mediately flash frozen. Tissues were scanned on the
Odyssey imaging system to discern changes in adiponec-
tin localization before homogenization in RIPA buffer.
Homogenated protein concentrations were measured by
BCA assay according to the manufacturer’s protocol
(Thermo Scientific) and normalized across equivalent
tissues (i.e., liver to liver or brain to brain). Following
normalization, 2 μL of homogenate was dot blotted in a
nitrocellulose membrane and scanned on the Odyssey.
Tissue results are expressed as adiponectin:IgG ratios.
Exercise studies
10 wildtype mice were exercise trained at low impact
(<10 m/min) on a Exer-6 M treadmill (Columbus Instru-
ments) following acclimatization every other day for one
week to increase treadmill time from 1 hour to 2 hours.
For the experiment, mice we i.v. injected with 0.05 μg/g
IR800-labeled HMW adiponectin or saline vehicle and
run at 16 m/min for 2 hours. Mice were sacrificed and a
fresh set of skeletal muscles were scanned on a LI-COR
Odyssey for IR800 adiponectin. The other set of muscles
were flash frozen and later measured for ceramide con-
tent. Triceps and quadriceps represent glycolytic mus-
cles while gastrocnemius (whole; a mix of fiber types)
and soleus are oxidative.
Ceramide content
Total ceramide content was quantified from lipid extracts
of exercised skeletal muscles analyzed by LC/MS with a
TSQ Quantum Ultra-triple quadrupole mass spectrometer
outfitted with an electrospray ionization probe as de-
scribed previously [27]. Ceramide content is reported as
summation of C14:0-C24:0 ceramide species on a per
muscle tissue mass basis.
Statistical analysis
Transport and circulatory data were analyzed by two-way
analysis of variance (ANOVA) using GraphPad Prism soft-
ware. For in vitro analyses, oligomer size and cell type
were used as variables. For circulation quantifications,
time and treatment were used as variables; tissue andtreatment were used as variables for tissue uptake. Bonfer-
roni post-hoc analyses of multiple comparisons were used
for all data. Differences in gene expression and tissue data
were analyzed by two-tailed student’s t-test with unequal
variance. Circulatory half-life determinations were calcu-
lated by non-linear regression analysis assuming an expo-
nential one factor decay model in Prism. Transwell data
are presented as box and whisker plots with error bars
representing the 95% confidence interval. Tissue data are
presented as means ± SD, while circulation graphs present
SE for graph visual clarity. Significances are indicated
as *0.05 > p > 0.01, **0.01 > p > 0.001, ***p < 0.001 for adi-
ponectin oligomer differences with asterisks used similarly
to indicate significance versus MS1 cells.
Results
Adiponectin oligomers are large circulatory proteins
Under normal physiological conditions, adiponectin exists
in circulation as trimeric, hexameric (LMW), and high
molecular weight (HMW) oligomers. Mammalian HEK
293 T cells were necessary to achieve “full-length” (refer-
ring to the presence of all oligomers) recombinant murine
adiponectin. The fractional distribution of HMW, LMW
and trimer in the average production was assessed by
gel filtration FPLC and subsequent immunoblotting of
collected fractions (Figure 1A). HMW adiponectin was
the dominant oligomer (71%) found in the recombinant
protein production (Figure 1B). Purified complexes were
isolated by repeated collection and pooling of the repre-
sentative species’ elution. The resultant purified, con-
centrated oligomer preparations were analyzed by the
same gel filtration FPLC method and demonstrated pu-
rities of 85%, 54%, and 54%, respectively, for the HMW,
LMW, and trimeric preps (Figure 1B).
Diffusive transport of adiponectin through solution is
determined by each oligomer’s Stokes radius. The Stokes
radii of purified adiponectin complexes were measured
by dynamic light scattering (DLS) and compared to
other common circulatory proteins as well as linear
known-size dextran molecules. The estimated molecular
weights of each known species by DLS agreed with the
published molecular weights of each respective standard
molecule (Figure 1C). Adiponectin oligomers exhibited a
linear relationship of estimated Stokes radii to molecular
weight that is characteristic of globular proteins. Tri-
meric adiponectin was measured to have a Stokes radius
of 3.96 nm, just slightly greater than albumin (3.33 nm).
LMW adiponectin was approximately 200 kDa or 6.01 nm,
a size larger than that measured for murine IgGs (5.09 nm).
The HMW adiponectin preparation was very large, exhi-
biting an estimated molecular weight of nearly 800 kDa.
The broad molecular weight size range measured was
likely from the presence of 12-, 18-, 24- and 36-mers gen-
erally described – and isolated – as the HMW complexes.
Figure 1 (See legend on next page.)
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Figure 1 Production and characterization of murine adiponectin oligomers. A) Western blot of gel fractionated adiponectin oligomers from
a full-length preparation. The highest molecular weight form elute first (left to right). Fractions representing HMW, LMW, and trimer adiponectin
were pooled for their respective purifications. Dotted lines mark typical fraction cut-offs for pooling. The band for 28 kDa molecular weight marker
(from the Bio-Rad 2 color ladder) is noted. The less intense slower band labeled is N-glycosylated – both bands were included in intensity
quantification. B) Quantitation of oligomer distribution in purified preparations used in experiments; data are presented as 0th order, 2-neighbor
smoothed curves for clarity. Percent distributions were calculated from raw intensity data with peaks separated by fraction intensity peak valleys
of the full-length form. C) Dynamic light scattering measurements of purified adiponectin oligomers yield estimated Stokes radii and molecular
weights. Murine IgGs, albumin, and linear known-length dextran molecules were measured for comparison. All of the proteins – including
adiponectin – followed a globular protein relationship while the dextrans fit a linear molecule relationship.
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globular proteins with the physical appearance of a
bunch of tightly-held balloons [28], their transport ra-
dius of 10.1 nm did not increase as varyingly as the mo-
lecular weights. These large Stokes radii should limit
adiponectin flux across endothelium and are highly rele-
vant to the systemic fate of adiponectin in circulation.
Adiponectin transport across murine endothelial cells is
actively limited
Model murine endothelial cell lines were used to quan-
tify adiponectin oligomer transport across endothelial
cell monolayers. MS1 cells were originally derived from
pancreatic islets, Bend cells from the brain, and EOMA
cells from a hemangioendothelioma – each cell line thus
from tissues that exhibit differing molecular permeabil-
ity. In culture, each cell line demonstrated clear endo-
thelial cell cobblestone morphology at confluence and
VE-cadherin expression at cell-cell junctions (Figure 2A).
Each limited the transport of inert 3 kDa and 70 kDa
dextran molecules when used in transwell permeability
pilot assays for at least 8 hours (Figure 2B).
The permeability of each cell line to HMW and LMW
adiponectin was quantified using transwell assay cultures
at 37°C for 6 hours and measuring the transported species
as described in the Methods. Quantified permeability of
adiponectin across the model endothelial cells lines were
subjected to a two-way analysis of variance having three
types of cells and two types of oligomer (Figure 2C).
Endothelial cell monolayer permeability to adiponectin
was found to be both significantly dependent on cell type
(p = 0.013) and oligomer size (p = 0.031). Bonferroni post-
hoc analysis demonstrated a significant increase in LMW
adiponectin transport over the HMW preparation across
only MS1 cells (p < 0.01). Transport of HMW adiponectin
across EOMA cells was significantly greater than MS1 or
Bend cells (p < 0.01). Upon comparing the ratios of adipo-
nectin permeability to those of a 70 kDa dextran tracer by
the same analysis (Figure 2D), however, cell type was no
longer significant (p = 0.185), but the adiponectin oligo-
mer effect was more pronounced (p < 0.001). The ratio of
HMW adiponectin:dextran across MS1 cells was signifi-
cantly less than LMW (p < 0.05). HMW adiponectin again
exhibited increased transport across EOMA cells thanMS1 or Bend cells (p < 0.05). It should be noted that be-
cause each adiponectin preparation did not consist 100%
of a single oligomer size, the calculated Peff may only be
approximate. In all instances, adiponectin transport was
far lower than dextran transport.
Commercially available globular adiponectin (gAPN)
lacks the characteristic collagenous domain of endogenous
adiponectin in circulation. To demonstrate the limitations
of full-length adiponectin oligomers to move across the
monolayer as opposed to gAPN, the permeability of gAPN
across the endothelial cell lines were measured (Figure 2E).
Compared to the permeability of our LMW adiponectin
preps by two-way ANOVA, gAPN was significantly
greater – more than a 3-fold increase – across all cells
lines (each p < 0.001 by Bonferroni post-hoc analysis). The
permeability was even greater than those of 70 kDa dex-
tran, highlighting the physiologic limitations of the smaller
recombinant form.
In experiments at 4°C, cell type was no longer signifi-
cant (Figure 2F; p = 0.070). Rather, oligomer size was
highly determinant of endothelial monolayer permeability
by two-way ANOVA (p < 0.001). Transport of LMW adi-
ponectin was significantly greater than the HMW form
across Bend and EOMA cells (p < 0.01 and p < 0.001, re-
spectively). ANOVA identified that only transport of
LMW adiponectin across Bend cells and HMW adiponec-
tin across EOMA cells were significantly affected by
temperature (both p < 0.001). LMW adiponectin perme-
ability across all of the cells matched that of dextran (ra-
tios near 1.0) suggested a loss of barrier function to
adiponectin at 4°C.
Dynasore, a dynamin inhibitor, was used at 37°C to
further explore active transport across the cells. Inhib-
ition of dynamin had a greater effect (p < 0.001) than cell
type (p = 0.0685) by ANOVA on the transport of full-
length adiponectin, with the most dramatic effect in
Bend cells (p < 0.05). With both cold temperature and
dynamin inhibition increasing adiponectin flux, the cells
must actively regulate or limit its passage.
Adiponectin action in endothelial cells
Confocal microscopy of full-length IR800-labeled adipo-
nectin revealed adiponectin to be localized to endothelial
cell-cell junctions in each of the cell line monolayers on
Figure 2 In vitro transwell assay to measure endothelial permeability to adiponectin complexes. A) Murine endothelial cell lines MS1,
bEnd.3 (Bend), and EOMA used in transwell assays to assess adiponectin flux exhibit different morphologies, but all demonstrate VE-Cadherin
(green) positive junctions that inhibit paracellular large molecule transport (DAPI, blue; Bar = 20 μm). B) 70 kDa and 3 kDa dextran flux across
MS1-seeded transwells over time normalizes concentrations above and below the cells in approximately 8 hours. 6 hours was chosen for transport
studies. C) Effective permeability (Peff) of LMW was significantly greater than HMW adiponectin across MS1 cells; HMW transport was greater across
EOMA as compared to MS1 at 37°C. D) Ratios of adiponectin permeability to that of 3 kDa dextran demonstrated increased LMW permeability as
compared to HMW in MS1 and Bend cells at 37°C. E) The Peff of globular adiponectin (gAPN) is significantly greater than that of full-length adiponectin
oligomers. F) The permeability of Bend and EOMA cells to LMW adiponectin was increased at 4°C, suggesting a loss of active barrier function for LMW
adiponectin; HMW transport was unchanged. G) As a ratio to dextran, LMW adiponectin transport was greatly enhanced at 4°C. H) Inhibition of
dynamin by Dynasore greatly enhanced full-length adiponectin transport in MS1 and Bend cells. No response was measured in EOMA cells. All analyses
were by two-way (cell, treatment) ANOVA with Bonferroni posthoc analysis. *p < 0.05, **p < 0.01 and ***p < 0.001 compared to HMW. #p < 0.05,
##p < 0.01 and ###p < 0.001 compared to MS1 cells.
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tial adiponectin within the cell layer, further indicating
active transport of adiponectin across the endothelial
monolayers. We measured the amount of bound or intra-
cellular adiponectin after 6 hours of incubation with full-
length adiponectin by image analysis of confocal maximum
projections (Figure 3A). Each cell line held a significant
quantity of adiponectin, with bEnd cells having significantlygreater than MS1 cells (p < 0.01) by one-way ANOVA
(Figure 3B). Media from atop a monolayer of MS1 cells
and below the transwell membrane after 6 hours were
sampled and fractionated by gel filtration FPLC (Figure 3C).
All 3 oligomer sizes were transported across the cells as
they were each detected in the bottom media. The adipo-
nectin distribution atop the transwell was predominantly
HMW, however, confirming the increased transport of the
Figure 3 Adiponectin uptake and modulation in endothelial cells. A) A significant amount of IR800-labeled adiponectin was found attached
or within endothelial cells following the transport experiments by confocal imaging of membranes (green = 70 kDa dextran, red = adiponectin).
Maximum projections are shown. B) Quantified adiponectin+ area on membranes; Bend cells bound or contained significantly more adiponectin
than MS1 cells by ANOVA of image intensity analysis. C) After 6 hours of full-length adiponectin transport across MS1 cells, media from above the
monolayer (top) and below the cells and membrane (bottom) was fractionated by gel filtration FPLC. Limited HMW was found to have crossed
the cells. 3 samples were pooled for fractionation. D) No change in Cdh5 gene expression was noted in the cells with adiponectin. Bend and
EOMA cells had increased Ocln expression as compared to MS1 cells with adiponectin. These cells also increased Tjp1 expression with adiponectin.
E) Nos3 was regulated by adiponectin in EOMA cells. No changes were measured in Cav1. (F) Adiponectin receptors 1 and 2, respectively, were
not regulated at the mRNA level by adiponectin treatment except for Adipor2 in EOMA cells. Cadh13 expression was not regulated by adiponectin
in the cells. Gene comparisons were made by two-tailed student’s t-test with unequal variance. *p < 0.05 and **p < 0.01 with adiponectin.
#p < 0.05 compared to MS1 cells.
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measured with purified preparations (Figure 2C) across
MS1 cells.
Adiponectin has been shown to regulate the expression
of adhesion molecules in endothelial cells and thus may
directly regulate transendothelial fluid transport. RNA
extracted from transwell cultures after 6 hours in the
presence or absence of recombinant full-length murineadiponectin demonstrated no marked changes in the
RNA expression of the cell-cell junction proteins VE-
cadherin (Cdh5) or occludin-1 (Ocln), but induced a sig-
nificant decrease in Tjp1 RNA for the junctional protein
ZO-1 in Bend cells (p = 0.040) and increase in EOMA
cells (p = 0.004; Figure 3D). Ocln levels in Bend and
EOMA cells were significantly higher with adiponectin
than in MS1 cells (p = 0.031 and p = 0.014, respectively).
Figure 4 Adiponectin oligomer distribution from different
venous collections. Sera collected from the tail vein, portal vein,
and left ventricle of 5 mice under anesthesia was gel fractionated by
FPLC and oligomer distributions quantified. The tail vein had
significantly more LMW and less trimeric adiponectin than the portal
circulation. Adiponectin trimers were also reduced at the heart
compared to portal vein. Percent abundance was calculated as the
summed intensity of peaks by immunoblot over the total intensity
of the 24 eluted fractions; analysis by two-tailed student’s t-test with
unequal variance. *p < 0.05 as indicated.
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may regulate vascular tone through nitric oxide in vivo,
was significantly increased in EOMA cells (p = 0.003).
Caveolae are necessary for the active transendothelial
transport of albumin and other proteins; its mRNA ex-
pression was not altered with adiponectin in any of the
cells (Cav1; Figure 3E). Though it is unclear what role
the adiponectin receptors play in cellular uptake of adi-
ponectin, each of the endothelial cell lines was found to
express AdipoR1, AdipoR2, and T-Cadherin (Cdh13).
Expression of the receptors was not significantly regu-
lated by exposure to adiponectin in the individual cell
lines, with the exception of increased Adipor2 mRNA in
EOMA cells (p = 0.046; Figure 3F). Even at basal meta-
bolic conditions, adiponectin did exhibit some alter-
ation in junctional molecule mRNA expression and
some potential changes in nitric oxide production or
adiponectin receptor expression, suggesting that these
factors that regulate endothelial physiology may be fur-
ther regulated in metabolic dysfunction.Adiponectin tissue uptake from circulation is dependent
on vasoregulation and transport
We recently demonstrated that the clearance of infused
adiponectin from circulation was dependent on oligomer-
size [18]. Having quantified adiponectin transport across
endothelial monolayers and found significant differences
between cell types and oligomer size, we sought to deter-
mine if different tissues preferentially take up adiponectin
oligomers. Gel fractionation and quantification of en-
dogenous adiponectin complex distribution in sera col-
lected from the tail vein, portal vein, and left ventricle
demonstrated significant differences in the relative oligo-
mer abundance of LMW and trimer species (Figure 4).
One-way ANOVA identified significant differences be-
tween the tail and portal circulation (p < 0.05) and signifi-
cantly less trimer at the left ventricle than in portal sera
(p < 0.05). This suggests that adiponectin complex dis-
tribution changes by location and likely reflects the dif-
ferential clearance of the adiponectin complexes across
the endothelia in different tissues. While supportive, we
cannot rule out that adipose tissues from different ana-
tomical regions contribute differential complements of
adiponectin complexes to the circulating pool.
To further quantify changes in circulating adiponectin
in vivo, we assessed the circulatory half-life and tissue
uptake of exogenously delivered IR800-labeled adiponectin
when endothelial barrier function was pharmacologically-
modulated. Following co-injection with an IR700-labeled
mouse IgG, sera were sampled over 180 minutes. Col-
lected sera were separated by gel electrophoresis to quan-
tify adiponectin:IgG ratios and half-lives (Figure 5A).
Perfused tissues were excised and the homogenate wassimilarly quantified by dot blot to assess tissue-specific up-
take relative to IgG (Figure 5B).
Acute oral treatment with isosorbide dinitrate to induce
vasodilation did not have a dramatic change on the circu-
latory clearance of either HMW or LMW adiponectin
(Figure 5C). Calculated half-lives from this clearance data
by non-linear regression analysis identified a significant
reduction in the half life of HMW adiponectin, from 53.7
to 24.0 minutes, with nitroglycerine (p = 0.001; Figure 5D).
No significant changes were quantified in LMW adipo-
nectin half life. Quantification of labeled adiponectin
uptake into tissues demonstrated uptake primarily into
liver and kidney with no significant differences de-
tected between vehicle and isosorbide dinitrate treat-
ment for HMW adiponectin (Figure 5E). Uptake of
LMW adiponectin, regardless of treatment, was lower
than HMW into most tissues as compared to the
mouse livers (Figure 5F). Isosorbide dinitrate treatment
did not significantly alter uptake of LMW adiponectin
in the tissues surveyed.
PPARγ agonists are potent in restoring insulin sensi-
tivity but have been limited clinically due to the changes
in peripheral water balance and endothelial permeability
with chronic use [29,30]. We utilized a 1-week nTZD
treatment to determine if these conditions improved adi-
ponectin flux into tissues. A marked retention of HMW
adiponectin was noted with PPARγ agonism (Figure 5G).
Indeed, the quantified half life was significantly extended
from 44.4 to 132.1 minutes (p = 0.026; Figure 5H). No
equivalent change was measured in LMW adiponectin,
suggesting that HMW transport may be actively modu-
lated by PPARγ agonist treatment or that differential
Figure 5 Tracking labeled adiponectin oligomer circulatory clearance and tissue uptake over time. A) Representative IR800-labeled
adiponectin (green) and IR700-labeled IgG (red) over time from sera separated by gel electrophoresis; Iso: isosorbide dinitrate treatment. B) Three
hours after injection, and following PBS perfusion, whole tissue was scanned to assess potential changes in adiponectin (green) localization and
tissue homogenates, normalized for total protein concentration, were measured by dot blot quantification. Data are presented as adiponectin:IgG
(red) ratio. C) Adiponectin:IgG ratios in sera over time following HMW (red lines) adiponectin or LMW (green lines) injection following acute
vehicle (solid lines) and isosorbide dinitrate (Iso; dotted lines) administration. D) The half-life of HMW adiponectin was significantly reduced with
iso treatment. E) Adiponectin:IgG ratios in tissues 3 hours following HMW adiponectin injection and normalized to liver values show no differences.
F) Similarly, no differences were noted for LMW tissue uptake with isosorbide dinitrate. G) Adiponectin:IgG ratios in sera over time following HMW (red
lines) adiponectin or LMW (green lines) injection into chow fed and PPARγ agonist (nTZD) diet fed (dotted lines) mice showed a delay in HMW
clearance. H) Quantified half-lives demonstrated a significant decrease in HMW adiponectin clearance from circulation. I) nTZD treatment increased
HMW adiponectin uptake in mouse brains. J) Conversely, nTZD-treated brains had significantly less LMW adiponectin uptake. Quadriceps also
contained less adiponectin with the PPARγ agonist. Half-lives quantified by non-linear regression (decay) analysis. All values compared by two-tailed
student’s t-test with unequal variance. *p < 0.05 between treatment and control.
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forms. nTZD treatment also generally increased tissue
uptake of HMW adiponectin as compared to chow diet,
with significant elevations being identified in the brain
(p = 0.015; Figure 5I). The brain surprisingly exhibited
reduced uptake of LMW adiponectin (p = 0.023) upon
nTZD treatment (Figure 5J). This dichotomous response
may be regulated by the yet unknown changes in the
adiponectin transport mechanism with PPARγ agonism
identified in the half life calculation.
Caveolin-1 knockout mice have increased endothe-
lial permeability due to increased paracellular albumin
flux across the endothelium [25]. Surprisingly, this had
no effect on adiponectin clearance from circulation
(Additional file 1: Figure S1A). Neither HMW nor LMWoligomers demonstrated statistically different changes in cir-
culation time with genotype (Additional file 1: Figure S1B)
suggesting that adiponectin and albumin are transported
differently across endothelium. HMW tissue uptake was
significantly increased in the livers of caveolin-1 knock-
out mice (p = 0.023; Additional file 1: Figure S1C), but
in no other tissues measured. No changes in tissue distribu-
tion of LMW adiponectin were measured (Additional file 1:
Figure S1D). While few significant differences were mea-
sured in half life or tissue uptake under the three condi-
tions tested, these data demonstrate that adiponectin
transport is certainly affected by changes in endothelial
permeability and suggest that tackling dysfunctional endo-
thelium pharmacologically may yield even greater changes
in transendothelial flux.
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exercise
According to a vast catalogue of literature, regulating
skeletal muscle metabolism is a key action of adiponectin
in insulin sensitization [31] and this response may be
driven by adiponectin’s ability to lower cellular ceramide
levels [27]. While our data have identified significant trans-
port barriers of adiponectin across endothelium in vitro,
our in vivo studies have demonstrated minimal changes in
adiponectin uptake into skeletal muscle (Figure 5). Exer-
cise is a condition with increased skeletal muscle blood
flow, metabolism and ceramide content. To test whether
the increasing blood flow to skeletal muscle might demon-
strate increased adiponectin action there, IR800-labeled
HMW adiponectin was administered to exercise-trained
mice immediately prior to a two-hour run. At sacrifice,
the tissue intensity of adiponectin label was significantly
increased in tricep (p = 0.006), quadricep (p = 0.042),
gastrocnemius (p < 0.001) and soleus (p = 0.010) muscles
(Figure 6A). Presence does not demonstrate function, so
the total tissue ceramide content was measured by LC/
MS. Quantified ceramide levels were significantly de-
creased with adiponectin treatment in soleus (p = 0.033)
and a trend towards reduction in gastrocnemius muscleFigure 6 HMW adiponectin uptake and function in skeletal
muscle with exercise. A) Significantly greater concentrations of
IR800-labeled HMW adiponectin were measured in the tricep,
quadricep (quad), gastrocnemius (gastroc) and soleus muscles of
mice that had run for 2 hours following tail vein infusion as
compared to rested mice. Density calculated by direct tissue scan.
B) Total tissue ceramide content (C16:0-C24:0) of oxidative muscles
was significantly reduced by adiponectin with the greatest effect
being observed in isolated soleus muscle. *p < 0.05, **p < 0.01 and
***p < 0.001 as compared to controls by two-tailed student’s t-test
with unequal variance.(p = 0.114) was measured. These oxidative muscles gener-
ate the most ceramide species, are highly responsive to
adiponectin’s ceramidase induction and benefit the most
from enhanced adiponectin uptake with exercise.Discussion
Here we report quantified transport sizes of adiponectin
oligomers and demonstrate the endothelium to be a po-
tent barrier to adiponectin transport. Numerous exam-
ples of changes in endothelial permeability to fluids and
proteins have been noted with changes in metabolic
state. The differential uptake of critical regulatory hor-
mones – notably insulin [17,32] – and the active binding
and transendothelial transport of fatty acids [33] to skel-
etal muscle is highly endothelial ‘health’ dependent. The
size of adiponectin oligomers makes adiponectin a prime
protein candidate for tight transport control. Indeed, of
all proteins secreted by adipose tissue, adiponectin was
the outlier demonstrating marked partitioning into blood
despite its size (as opposed to the passive enrichment of
other adipokines in lymph) suggesting active and prefer-
ential uptake by blood endothelium [34]. Beyond adipo-
cyte secretion, circulatory uptake and clearance may be
mechanisms behind changes in the distribution of circu-
lating adiponectin complex measured here locally and sys-
temically in, for example, the caveolin-1 knockout mouse
[20]. Our in vitro data demonstrate that adiponectin oligo-
mers are actively transported across different endothelium
with differing efficiency and may be excluded or very lim-
ited; PPARγ agonism may change this mechanism. Our
data also demonstrate a strong size-dependent regulation
of adiponectin uptake from circulation. In vivo, small per-
turbations in endothelial barrier function or vessel dilation
(and concomitant changes in microvascular flow rates)
may regulate local tissue uptake. Adiponectin itself may
signal in this regulation of local endothelial and tissue me-
tabolism [35], most interestingly through the emerging
adiponectin-sphingolipid axis which plays a role in endo-
thelial function [36,37].
Existing data supports a strong correlation between
cardiovascular health and endothelial responsiveness.
Serum nitric oxide levels are greatly reduced with obes-
ity and T2DM, for example; and skeletal muscle nitric
oxide levels scaled with serum adiponectin levels [38].
Adiponectin uptake into tissue was not altered greatly
with pharmacologic treatments in healthy mice, but was
significantly increased with exercise and demonstrated
potent ceramidase activity in this setting. Exercise, which
increases both blood flow to muscle as well as nutrient
flux, and healthy vascular tone may be necessary for the
reported HMW adiponectin efficacy in skeletal muscle
[39]. The combined data suggest that endothelial dysfunc-
tion in the metabolic syndrome may inhibit adiponectin
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ford a target for enhancing adiponectin clearance.
Our tissue distribution data demonstrated changes in
both HMW and LMW adiponectin uptake in the brain.
Based on the full tissue scans and regional permeability,
we hypothesize that this is uptake into the hypothalamus:
hypothalamic adiponectin signaling has been identified as
a potential regulator of glucose homeostasis and energy
balance [40-42] and signaling throughout the brain may
regulate mood and other processes [43,44]. Sampling of
cerebral spinal fluid, however, found only trimeric adipo-
nectin [45] and suggested that some reduction of adipo-
nectin complexes is necessary to adiponectin to access the
brain. Our data found that PPARγ agonism increased cir-
culating HMW adiponectin and increased brain tissue
levels; a concentration gradient driven flux is unlikely
given the amounts injected. Indeed, proteolytic action on
adiponectin oligomers has been suggested to direct adipo-
nectin activity [46,47]; regulation of proteolytic activity
with metabolic state may control HMW adiponectin
clearance. Globular adiponectin, which already lacks the
collagenous domain cleaved by digestion, is a potent in-
ducer of adiponectin effects in muscle cells [48,49] but
may have limited physiologic relevance as it would bypass
these regulated transport sequences when studied in vivo.
Flux of adiponectin from adipose tissue or from the
circulation into target tissue may play a role in the com-
position of circulating adiponectin. Fractionation of adi-
ponectin complexes has identified that circulating levels
of HMW adiponectin, or the ratio of HMW to trimer,
may be the best indicator of insulin sensitivity and meta-
bolic flexibility [2,3,6,20]. While these conclusions re-
main valid, recent studies have identified populations
and BMI levels where this correlation is more significant
with fat mass than disease state [50,51]. Other patholo-
gies, such as chronic kidney disease, have also broken
this general correlation [4]. Endothelial health and trans-
port, levels of adiponectin receptor expression and bind-
ing, or depot-specific production and uptake may dictate
complex clearance, distribution and function in these
populations and pathologies. The relationship between
adiponectin and endothelial function and metabolic re-
sponses continues to emerge [52].Conclusions
Adiponectin bioavailability for target cells under meta-
bolically challenging conditions is reduced due to re-
duced trans-endothelial transport and may represent a
subtle target for improving insulin sensitivity. Under-
standing adiponectin transport into and across these cells
holds important clues towards understanding the systemic
physiological effects of this important adipocyte-derived
secretory protein and may further reinforce adiponectinas a predominant hormonal link between adipose tissue
health and cardiovascular disease.
Additional file
Additional file 1: Figure S1. Tracking labeled adiponectin oligomer
circulatory clearance and tissue uptake over time in wild type and Cav1
knockout mice (Cav-/-). A) Adiponectin:IgG ratios in sera over time
following HMW (red lines) adiponectin or LMW (green lines) injection
into wildtype (WT; solid lines) and caveolin-1 knockout mice (Cav; dotted
lines). B) Lack of caveolar trafficking had no effect on either adiponectin
complex half life. C) HMW adiponectin tissue distribution was unchanged
in Cav -/- mice. D) LMW adiponectin concentration was increased in the
brains of Cav-1 KO mice. Analyses by two-tailed student’s t-test with
unequal variance. * p<0.05. Table S1. Primer sequences used for quantitative
PCR measures in murine endothelial cells.
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